Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenilate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients

Trial Profile

Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenilate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 03 May 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Rituximab (Primary) ; Mycophenolate mofetil; Sirolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms RESTARRT
  • Most Recent Events

    • 03 May 2017 Early results presented at the 2017 American Transplant Congress
    • 04 Feb 2016 Planned End Date changed from 1 Oct 2018 to 1 Jun 2020 as reported by ClinicalTrials.gov record.
    • 04 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top